Seroatlas · Human Serome Atlas

IGFBPL1

Insulin-like growth factor-binding protein-like 1

Also known as: bA113O24.1, IBPL1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8WX77
Gene: IGFBPL1
Ensembl: ENSG00000137142
Chromosome: 9
Canonical length: 278 aa
Protein class: Predicted secreted proteins
Subcellular location: Nucleoplasm,Vesicles
Secretome location: Secreted to blood

OverviewNCBI Gene

Predicted to enable insulin-like growth factor binding activity. Involved in cellular response to tumor cell. Located in extracellular space. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

278 residues, UniProt reviewed canonical sequence.

>Q8WX77|IGFBPL1
     1  MPRLSLLLPL LLLLLLPLLP PLSPSLGIRD VGGRRPKCGP CRPEGCPAPA PCPAPGISAL
    61  DECGCCARCL GAEGASCGGR AGGRCGPGLV CASQAAGAAP EGTGLCVCAQ RGTVCGSDGR
   121  SYPSVCALRL RARHTPRAHP GHLHKARDGP CEFAPVVVVP PRSVHNVTGA QVGLSCEVRA
   181  VPTPVITWRK VTKSPEGTQA LEELPGDHVN IAVQVRGGPS DHEATAWILI NPLRKEDEGV
   241  YQCHAANMVG EAESHSTVTV LDLSKYRSFH FPAPDDRM

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against IGFBPL1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.41
Highest tissue expression: 16 nTPM

Expression across tissuesHPA

Tissue

thyroid gland: 16 nTPM
blood vessel: 7.8 nTPM
basal ganglia: 5.4 nTPM
cerebellum: 3.9 nTPM
pituitary gland: 3.4 nTPM
thymus: 2.7 nTPM

Single-cell type

early spermatids: 25 nCPM
adrenal medulla cells: 21 nCPM
late spermatids: 21 nCPM
pancreatic islet cells: 21 nCPM
somatotrophs: 17 nCPM
hofbauer cells: 16 nCPM

Immune cell

basophil: 0.5 nTPM
neutrophil: 0.4 nTPM
gdT-cell: 0.2 nTPM
naive B-cell: 0.2 nTPM
NK-cell: 0.2 nTPM
plasmacytoid DC: 0.2 nTPM

Brain region

basal ganglia: 11 nTPM
cerebellum: 9.1 nTPM
hypothalamus: 8.1 nTPM
hippocampal formation: 7.6 nTPM
midbrain: 7.4 nTPM
cerebral cortex: 6.9 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.64
gnomAD pLI: 0
gnomAD missense Z: 0.44
DepMap mean gene effect: 0.01
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

insulin-like growth factor binding

Cellular components

extracellular space

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads IGFBPL1 as an antibody target. Whether an autoantibody or antibody against IGFBPL1 could matter depends on whether native IGFBPL1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

IGFBPL1 is annotated as secreted, so native IGFBPL1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label IGFBPL1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...